Advice

Following a full submission

sunitinib (Sutent®) is not recommended for use within NHS Scotland for the treatment of advanced and/or metastatic renal cell carcinoma (MRCC). In a planned interim analysis, sunitinib improved progression-free survival and objective response rate when compared with interferon alfa. However, as yet there is insufficient information available on overall survival.

The manufacturer did not present a sufficiently robust economic analysis and their justification of the treatment’s cost in relation to its health benefits was not sufficient to gain acceptance by SMC.

The licence holder has indicated their decision to resubmit.

Download detailed advice79KB (PDF)

Download

Medicine details

Medicine name:
sunitinib 12.5mg, 25mg, 50mg capsules (Sutent)
SMC ID:
384/07
Indication:
First line treatment of advanced and/or metastatic renal cell carcinoma (MRCC)
Pharmaceutical company
Pfizer Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Status
Superseded
Date advice published
09 July 2007